How do I calculate the starting dose of basal insulin?

How to Calculate Starting Dose of Basal Insulin

For most adults with type 2 diabetes starting basal insulin, use 0.1–0.2 units/kg/day when A1C is <8%, or 0.2–0.3 units/kg/day when A1C is ≥8%, administered as a long-acting analog such as glargine or degludec. 1

Weight-Based Dosing Algorithm

Standard Starting Doses by A1C Level

• A1C <8%: Start at 0.1–0.2 units/kg/day 1, 2, 1, 3

  • For a 70 kg patient: 7–14 units daily
  • For an 80 kg patient: 8–16 units daily

• A1C ≥8%: Start at 0.2–0.3 units/kg/day 1, 3

  • For a 70 kg patient: 14–21 units daily
  • For an 80 kg patient: 16–24 units daily

Dose Reductions for High-Risk Populations

Reduce the starting dose to 0.1–0.2 units/kg/day (regardless of A1C) in patients who are: 4

• Age ≥70 years 4
• Glomerular filtration rate <60 mL/min 4
• At high risk for hypoglycemia (history of hypoglycemia unawareness, living alone, cognitive impairment) 3

Alternative Fixed-Dose Approach

• 10 units once daily is an acceptable simplified starting dose for any patient when weight-based calculation is impractical 2, 3, 5
• This conservative approach minimizes hypoglycemia risk while allowing subsequent titration 5

Severe Hyperglycemia with Symptoms

When A1C >10% and/or blood glucose ≥300 mg/dL with symptomatic hyperglycemia (weight loss, polyuria, polydipsia): 1

• Start basal insulin at 0.2–0.3 units/kg/day 1
• Add prandial insulin before the largest meal at 5 units or 10% of the basal dose 1
• Do not use GLP-1 receptor agonists alone in this setting, as they require titration and delay glucose control 1
• Consider testing for autoimmune (type 1) diabetes 1

Titration Strategy

Standard Titration Schedule

Adjust the basal dose every 2–3 days for first-generation analogs (glargine U100, detemir, NPH): 1, 2, 3

Fasting Glucose (mg/dL)	Dose Adjustment
>180	Increase by 20% of total daily dose [1]
140–180	Increase by 10% of total daily dose [1]
110–139	Increase by 1 unit [1]
<70	Decrease by 10–20% [1]
<40	Decrease by 20–40% [1]

Slower Titration for Second-Generation Analogs

For glargine U300 or degludec U100/U200, titrate every 3–5 days because these formulations require longer time to reach steady state 1, 2, 1, 3

Simplified Fixed-Increment Method

• Increase by 2 units every 3 days until fasting glucose target is achieved 1, 2, 5
• This approach is easier for patients to self-manage 2, 5

Target Fasting Glucose

• <110 mg/dL without hypoglycemia for most patients 1, 3
• 90–130 mg/dL is an acceptable alternative range 2
• 90–150 mg/dL for older adults or those with comorbidities and high hypoglycemia risk 3

Avoiding Over-Basalization

Do not increase basal insulin beyond 0.5–1.0 units/kg/day without meaningful reduction in fasting glucose. 1, 3, 5

Clinical Indicators of Over-Basalization

• Bedtime-to-morning glucose differential ≥50 mg/dL 1, 3
• Persistent hypoglycemia (aware or unaware) 1, 3
• High glucose variability despite high basal doses 1, 3

Management When Over-Basalization Occurs

• Add prandial insulin before meals rather than further increasing basal insulin 1, 3
• Add a GLP-1 receptor agonist to improve postprandial control and reduce total insulin requirements 2, 1, 3
• Consider switching to a fixed-ratio combination of basal insulin and GLP-1 RA (iGlarLixi or IDegLira) 2

Preferred Basal Insulin Formulations

Long-acting analogs (glargine, degludec, detemir) are strongly preferred over NPH insulin because they reduce nocturnal and overall hypoglycemia by 20–40% while providing equivalent or superior glycemic control 3, 6

First-Line Choices

• Glargine U100, glargine U300, degludec U100/U200, or detemir are all appropriate first-line options 3, 6
• Glargine U300 or degludec are preferred in patients at higher hypoglycemia risk (elderly, renal impairment, hypoglycemia unawareness) 3

When to Use Concentrated Formulations

• Glargine U300 or degludec U200 when daily insulin requirements exceed 0.5 units/kg or 200 units total, allowing larger doses in smaller injection volumes 3

NPH Insulin as Alternative

• NPH insulin is acceptable only when cost prohibits analog use, but it carries substantially higher hypoglycemia risk and requires twice-daily dosing 3, 6

Concomitant Medication Management

Discontinue at Insulin Initiation

• Stop sulfonylureas immediately when starting basal insulin to avoid additive hypoglycemia risk 3
• Discontinue other oral diabetes medications in hospitalized patients 4

Continue or Add

• Continue metformin with basal insulin to attenuate weight gain and reduce insulin dose requirements 3
• Add or continue GLP-1 receptor agonist for greater A1C reduction, weight loss, and lower hypoglycemia rates compared with insulin alone 2, 3

Hospitalized Patients (Non-Critical Care)

For non-critical care inpatients with blood glucose >140 mg/dL who are eating: 4

• Start basal insulin at 0.2–0.3 units/kg/day for most patients 4
• Reduce to 0.2 units/kg/day for patients aged ≥70 years or GFR <60 mL/min 4
• Increase to 0.4 units/kg/day when glucose is 140–200 mg/dL 4
• Increase to 0.5 units/kg/day when glucose is 201–400 mg/dL 4
• Distribute total dose as 50% basal insulin and 50% nutritional (prandial) insulin 4

For patients who are NPO (not eating): 4

• Give basal insulin alone with correction doses of rapid-acting analog every 4 hours or regular insulin every 6 hours 4

Common Pitfalls to Avoid

• Do not rely on sliding-scale correction insulin alone without scheduled basal insulin; this reactive approach leads to poor control and worse outcomes 4, 3, 7
• Do not give NPH at bedtime in older adults, as the peak effect (2–6 AM) raises nocturnal hypoglycemia risk 7
• Do not continue escalating basal insulin beyond 0.5 units/kg/day if fasting glucose remains elevated; the problem is likely insufficient prandial coverage 3, 5
• Do not target morning fasting glucose alone when titrating basal insulin; monitor afternoon and evening glucose to avoid over-basalization 1